21 CFR 201.66: Drug Facts Sections, Format, and Small Packages

The Food and Drug Administration’s drug facts labeling requirements at 21 CFR 201.66 set the exact content, order, and visual format of the “Drug Facts” panel that must appear on every over-the-counter drug sold in the United States.¹ The rule locks in eight labeled sections in a fixed sequence, dictates type sizes and layout down to bullet shape, and treats any noncompliant product as misbranded under federal law.²

Which Products Have to Comply

Every OTC drug product falls under 21 CFR 201.66, no matter how simple the formula. Manufacturers, contract packers, and private-label distributors all share the compliance obligation, and any of them can be held responsible if a noncompliant product reaches the market.¹

Products sitting on the drug-cosmetic border are included too. Anti-dandruff shampoos, moisturizers with SPF, and acne washes all make therapeutic claims, which makes them OTC drugs and puts them under the Drug Facts panel rule. For those combination products, inactive ingredients follow a different ordering convention that reflects cosmetic labeling practice. Where drug labeling rules and cosmetic labeling rules disagree, the Drug Facts requirements control.

The Eight Required Sections and Their Order

The label must present these headings in this exact sequence, and manufacturers cannot rearrange them:¹

Active ingredient(s), with the name and amount of each therapeutic substance per dosage unit (for example, “Acetaminophen 500 mg” per tablet).
Purpose(s), stating the pharmacological category or intended action, such as “pain reliever” or “nasal decongestant.”
Use(s), describing the symptoms or conditions the product treats.
Warnings, consolidating all safety information under a set of required subheadings.
Directions, giving dose, frequency, and duration, typically broken out by age group.
Other information, covering details such as storage temperature and tamper-evident packaging. A typical storage statement reads “Store at 20–25°C (68–77°F).”
Inactive ingredients, listed by established name. Straight drugs list them alphabetically; drug-cosmetic combinations follow the cosmetic convention.
Questions?, an optional heading providing a phone number or other contact information. This is the only section that is not mandatory.

The fixed order is the point of the rule. A shopper who learns to find Warnings on one box finds it in the same place on every other box in the aisle.

How the Warnings Section Is Structured

Warnings is the most rule-bound part of the panel. Not every product needs every subheading, but the ones that apply appear in this order:¹

“For external use only” on topical products, with equivalent phrasing for rectal or vaginal products.
Specific-hazard alerts: a Reye’s syndrome warning on salicylates, allergy or asthma alerts where applicable, liver or stomach-bleeding warnings on certain pain relievers, and a dosage warning on products containing sodium phosphates.
“Do not use,” listing contraindications where the consumer should avoid the product entirely.
“Ask a doctor before use if you have,” covering preexisting conditions or symptoms that warrant medical advice first.
“Ask a doctor or pharmacist before use if you are,” covering drug-drug and drug-food interactions.
“When using this product,” describing expected side effects and activities to avoid, such as driving or drinking alcohol.
“Stop use and ask a doctor if,” listing signs of toxicity or reactions that call for discontinuing the product.

A pregnancy or breastfeeding warning follows if applicable, and the standard “Keep out of reach of children” statement closes the block. The layered structure lets a reader who knows they have no contraindications skip ahead to interactions or side effects without reading the full block.

Format and Design Rules

The regulation controls how the panel looks, not just what it says.¹

Type Sizes and Style

The “Drug Facts” title must be larger than any other text on the panel. Section headings like “Warnings” or “Directions” must be at least 8-point, or 2 points larger than the body text, whichever is bigger. Everything else, including subheadings and body copy, must be at least 6-point. Lines need at least 0.5 points of leading, letters cannot touch, and the panel must use a single clear typeface with no more than 39 characters per inch. The title and section headings appear in bold italic; subheadings such as “Do not use” appear in bold only. On a continuation panel, “(continued)” stays in regular weight.

Color, Bullets, and Enclosure

All text prints in black, or in one consistent color, on a white or contrasting background. The title and headings may use one alternative color for emphasis. The whole panel must be set off from surrounding artwork, typically with a box or contrasting background, so it doesn’t blend into marketing graphics. Bulleted items use solid 5-point square or circle bullets, and those bullets must be the same shape and color throughout the label.

Multi-Panel Layout

When the label runs across more than one panel, the continuation panel carries the title “Drug Facts (continued)” at the top, in at least 7-point type for the modified format or 8-point for the standard format. Hairlines separate sections. No promotional content or marketing art may enter the Drug Facts area.

Small Packages: Modified Format and Exemptions

Travel sizes, single-dose packets, and other tight containers get two forms of relief.

The first is the modified format. When the full Drug Facts labeling at standard specifications, plus any other FDA-required text, would occupy more than 60 percent of the available labeling surface, a manufacturer can switch to a modified format.¹ The modified format permits 7-point headings instead of 8, tighter line spacing so long as letters don’t overlap, multiple bulleted items on one line, and a contrasting background in place of an enclosing box. The content stays the same; only the graphics loosen.

The second is an FDA exemption or deferral. When even the modified format won’t fit, a manufacturer, packer, or distributor can submit a written “Application for Exemption” explaining why a specific requirement is impracticable or contrary to public health for that product. The FDA can also initiate exemptions on its own. Decisions are case by case and don’t extend automatically to a company’s other products. Fold-out labels and peel-back panels sometimes come out of this process.

What Happens When a Label Doesn’t Comply

A noncompliant label makes the product misbranded under 21 U.S.C. 352, and introducing a misbranded drug into interstate commerce is a prohibited act under 21 U.S.C. 331.³ From there, several enforcement tools apply:

Warning letters are the FDA’s usual first step, identifying violations and setting a deadline to correct them.⁴
Seizure allows federal courts to order the physical seizure and condemnation of misbranded drugs found in interstate commerce or held for sale after shipment.⁵
Injunctions let federal district courts order a company or individual to stop violating the law.⁶
Criminal penalties reach up to one year in prison, a fine of up to $1,000, or both, for a first offense. A repeat violation or one committed with intent to mislead rises to up to three years in prison and a fine of up to $10,000.⁷

Most labeling problems resolve at the warning-letter stage, once the company corrects the label and shows compliance. The criminal exposure sits at the far end for repeat or deliberate violations, while the seizure authority means the FDA can pull noncompliant products off shelves without waiting for a criminal case to develop.

1
eCFR. 21 CFR 201.66 – Format and Content Requirements for Over-the-Counter (OTC) Drug Product Labeling
2
Office of the Law Revision Counsel. 21 USC 352 – Misbranded Drugs and Devices
3
Office of the Law Revision Counsel. 21 USC 331 – Prohibited Acts
4
FDA. Warning Letters
5
Office of the Law Revision Counsel. 21 USC 334 – Seizure
6
Office of the Law Revision Counsel. 21 USC 332 – Injunction Proceedings
7
Office of the Law Revision Counsel. 21 USC 333 – Penalties